Trial · NCT07891377
HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid Malignancies
NCT07891377, Phase 2, Not yet recruiting, Sunshine Lake Pharma Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid Malignancies. Trials, record NCT07891377. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891377
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid Malignancies
- NCT number
- NCT07891377
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 160 participants, estimated
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.
- Conditions
- Chemotherapy-induced Anemia, Non-Myeloid Malignancy
- Interventions
- HEC53856 tablet, rHuEPO injection
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The compliance rate of hemoglobin (Hb) in trial participants at week 7 | Week 7 | The proportion of participants who met the hemoglobin (Hb) standard (defined as 100\<Hb ≤ 120 g/L) in the 7th week |
| Secondary | Hemoglobin (Hb) Response Rate | Up to around 15 weeks | The proportion of participants achieving Hb targets at each preset visit point during the trial period (including the study treatment end visit; excluding the 7th week) |
| Secondary | The average Hb compliance rate of participants at each preset visit point during the trial period | Up to around 15 weeks | During the trial, the average Hb target achievement rate at the preset study visits was calculated. |
| Secondary | Mean change of Hb | From Week 7 to around week 15 | Mean change from baseline in hemoglobin level assessed from Week 7 through the end-of-treatment visit. |
| Secondary | The proportion of trial participants with Hb increased by ≥10 / 15 / 20 g/L from baseline | Up to around 15 weeks | Proportion of participants achieving hemoglobin increase of at least 10 g/L, 15 g/L, or 20 g/L relative to baseline. |
| Secondary | The time when Hb increased by ≥10 /15/20 g/L compared to baseline | Up to around 15 weeks | Time from randomization to first occurrence of hemoglobin increase of at least 10 g/L, 15 g/L, or 20 g/L relative to baseline. |
| Secondary | The proportion of trial participants whose chemotherapy dosage is reduced or suspended due to anemia. | Up to around 15 weeks | Study the proportion of trial participants whose chemotherapy dosage is reduced or suspended due to anemia during treatment. |
| Secondary | Proportion of participants with non-response | From Week 5 to around week 15 | Proportion of participants meeting non-response criteria defined as requirement for red blood cell transfusion or hemoglobin less than 60 g/L, assessed from Week 5 to end of treatment. |
| Secondary | Number and volume of red blood cell transfusions | From baseline to around week 15 | Number of red blood cell transfusions and transfusion volume from baseline to the end of treatment. |
| Secondary | Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) | Up to around 15 weeks | Adverse events in this study will be evaluated according to CTCAE V6.0 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891377
GET https://conductscience.org/api/trials/v1/NCT07891377/registered